BRPI0409984A - processo para alterar a farmacocinética da insulina - Google Patents
processo para alterar a farmacocinética da insulinaInfo
- Publication number
- BRPI0409984A BRPI0409984A BRPI0409984-2A BRPI0409984A BRPI0409984A BR PI0409984 A BRPI0409984 A BR PI0409984A BR PI0409984 A BRPI0409984 A BR PI0409984A BR PI0409984 A BRPI0409984 A BR PI0409984A
- Authority
- BR
- Brazil
- Prior art keywords
- insulin
- processes
- present
- prevention
- treatment
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 12
- 102000004877 Insulin Human genes 0.000 title abstract 6
- 108090001061 Insulin Proteins 0.000 title abstract 6
- 229940125396 insulin Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 230000000291 postprandial effect Effects 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/46—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3286—Needle tip design, e.g. for improved penetration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Abstract
"PROCESSO PARA ALTERAR A FARMACOCINéTICA DA INSULINA". A presente invenção se refere a processos para a administração de insulina a um compartimento intradérmico da pelo de um indivíduo, de preferência à vascularização dérmica do compartimento intradérmico. Os processos da presente invenção aumentam os parâmetros farmacocinéticos e farmacodinâmicos da insulina distribuída e resultam eficazmente em uma eficácia clínica superior no tratamento e/ou prevenção de diabetes melito. Os processos da presente invenção proporcionam um melhor controle glicêmico tanto dos níveis de glicose sangüínea não em jejum (isto é, pós-prandiais), quanto em jejum e, portanto, têm uma maior eficácia terapêutica no tratamento, prevenção e/ou controle de diabetes, com relação a processos tradicionais de distribuição de insulina, incluindo a distribuição subcutânea de insulina.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/429,973 US7722595B2 (en) | 2002-05-06 | 2003-05-06 | Method and device for controlling drug pharmacokinetics |
| US50095603P | 2003-09-05 | 2003-09-05 | |
| US10/704,035 US20050010193A1 (en) | 2002-05-06 | 2003-11-06 | Novel methods for administration of drugs and devices useful thereof |
| US52383103P | 2003-11-19 | 2003-11-19 | |
| PCT/US2004/014033 WO2004101023A2 (en) | 2003-05-06 | 2004-05-06 | A method for altering insulin pharmacokinetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0409984A true BRPI0409984A (pt) | 2006-05-09 |
Family
ID=33459121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0409984-2A BRPI0409984A (pt) | 2003-05-06 | 2004-05-06 | processo para alterar a farmacocinética da insulina |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1620145A4 (pt) |
| JP (1) | JP2007517768A (pt) |
| KR (1) | KR20060009303A (pt) |
| AU (1) | AU2004238257A1 (pt) |
| BR (1) | BRPI0409984A (pt) |
| CA (1) | CA2524444A1 (pt) |
| MX (1) | MXPA05011768A (pt) |
| WO (1) | WO2004101023A2 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8465468B1 (en) | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
| US10105317B2 (en) * | 2009-07-07 | 2018-10-23 | Anpac Bio-Medical Science Co., Ltd. | Method of drug delivery |
| EP3134110A1 (en) * | 2014-04-25 | 2017-03-01 | Sanofi | New administration routes of insulin, insulin analogs or derivatives of insulin |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6623457B1 (en) * | 1999-09-22 | 2003-09-23 | Becton, Dickinson And Company | Method and apparatus for the transdermal administration of a substance |
| US20020156453A1 (en) * | 1999-10-14 | 2002-10-24 | Pettis Ronald J. | Method and device for reducing therapeutic dosage |
| US6565532B1 (en) * | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
| US6607513B1 (en) * | 2000-06-08 | 2003-08-19 | Becton, Dickinson And Company | Device for withdrawing or administering a substance and method of manufacturing a device |
| EP1381415A1 (en) * | 2001-04-13 | 2004-01-21 | Becton, Dickinson and Company | Method of intradermally injecting substances |
| CN1253220C (zh) * | 2001-06-29 | 2006-04-26 | 贝克顿迪肯森公司 | 通过微管在真皮内输入疫苗和基因治疗剂 |
| WO2003022330A2 (en) * | 2001-09-12 | 2003-03-20 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
-
2004
- 2004-05-06 EP EP04751427A patent/EP1620145A4/en not_active Withdrawn
- 2004-05-06 WO PCT/US2004/014033 patent/WO2004101023A2/en not_active Ceased
- 2004-05-06 BR BRPI0409984-2A patent/BRPI0409984A/pt not_active Application Discontinuation
- 2004-05-06 MX MXPA05011768A patent/MXPA05011768A/es unknown
- 2004-05-06 CA CA002524444A patent/CA2524444A1/en not_active Abandoned
- 2004-05-06 AU AU2004238257A patent/AU2004238257A1/en not_active Abandoned
- 2004-05-06 KR KR1020057021081A patent/KR20060009303A/ko not_active Ceased
- 2004-05-06 JP JP2006532794A patent/JP2007517768A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05011768A (es) | 2006-01-26 |
| CA2524444A1 (en) | 2004-11-25 |
| EP1620145A2 (en) | 2006-02-01 |
| WO2004101023A2 (en) | 2004-11-25 |
| KR20060009303A (ko) | 2006-01-31 |
| WO2004101023A3 (en) | 2007-03-01 |
| EP1620145A4 (en) | 2010-08-25 |
| JP2007517768A (ja) | 2007-07-05 |
| AU2004238257A1 (en) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bode et al. | Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes | |
| Hollander et al. | A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes | |
| Kann et al. | Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride | |
| Raskin et al. | Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs | |
| Garg et al. | Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine | |
| Raskin et al. | Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. | |
| McSorley et al. | Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus | |
| Bode | Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues—aspart, lispro, and glulisine | |
| Pitt et al. | Factors influencing insulin absorption around exercise in type 1 diabetes | |
| ES2334258T3 (es) | Control de la glucosa en sangre en el tratamiento de la diabetes que usa la insulina administrada pulmonarmente en combinacion con la insulina basal. | |
| Black et al. | The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation | |
| Maiorino et al. | Treatment satisfaction and glycemic control in young type 1 diabetic patients in transition from pediatric health care: CSII versus MDI | |
| NZ592283A (en) | Combination of an insulin and the GLP-1 agonist AVE0010 | |
| Woo | A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus | |
| Quaba et al. | A users guide for reducing the pain of local anaesthetic administration | |
| Davidson et al. | Biphasic insulin aspart 30: literature review of adverse events associated with treatment | |
| BRPI0409984A (pt) | processo para alterar a farmacocinética da insulina | |
| Ristic et al. | Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus | |
| Standl | Insulin analogues–State of the art | |
| Joshi et al. | Designer insulins regimens in clinical practice-pilot multicenter indian study | |
| Choe et al. | New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs | |
| Kapural et al. | Decreased insulin requirements with spinal cord stimulation in a patient with diabetes | |
| Cander et al. | The effect of basal analog insulin on the glycemic variability in type 2 diabetics. | |
| Cypryk et al. | New faster-acting insulin Fiasp®—do we need a new meal-time insulin? | |
| Faradji et al. | Use of Insulin in Outpatient Diabetes Management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal: dismissal of application maintained |